207940.KS
Samsung Biologics Co.,Ltd.
KSC · Healthcare · Biotechnology · KR
KRW 1,477,000.00
−1.60%Margins
Gross margin
55.5%
EBITDA margin
65.0%
EBIT margin
43.7%
Net margin
43.6%
FCF margin
35.4%
23.7%
Return on equity
15.7%
Return on assets
20.7%
Return on invested capital
0.37x
Asset turnover
KRW 2.43T
Cash from operations
KRW 47.3K
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026